Increlex (mecasermin) — Point32Health
Growth failure in pediatric patients with severe primary insulin-like growth factor-1 deficiency (Primary IGFD)
Initial criteria
- Documented diagnosis of one of the following: (a) growth hormone gene deletion with neutralizing antibodies to growth hormone OR (b) severe primary IGF-1 deficiency defined by height standard deviation score ≤ -3.0, basal IGF-1 standard deviation score ≤ -3.0, and normal or elevated growth hormone
- Patient age 2–17 years
- Prescribed by or in consultation with a pediatric endocrinologist
- Documentation that the patient has open epiphysis
Approval duration
until 18th birthday